Welcome to our dedicated page for Rocket Pharmaceu SEC filings (Ticker: RCKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rocket Pharmaceuticals, Inc. filings document regulatory, financial, governance, and capital-structure disclosures for a biotechnology company developing and commercializing genetic therapies for rare disorders. Recent 8-K reports cover quarterly and annual operating results, FDA-related events for KRESLADI, Priority Review Voucher monetization, and clinical-program updates for cardiovascular gene therapy candidates.
The filing record also includes definitive proxy materials for annual-meeting governance matters and material-agreement disclosures related to an at-the-market common stock offering program under a shelf registration statement. These documents describe board and shareholder-vote matters, equity financing mechanics, common stock structure, business risks, and formal disclosure controls around product approvals and development programs.
Rocket Pharmaceuticals reported a leadership change in its finance organization. Chief Financial Officer Aaron Ondrey resigned on August 20, 2025, with his departure effective September 5, 2025, as he leaves to pursue other opportunities.
On August 25, 2025, the company appointed Martin Wilson, its General Counsel, Chief Corporate Officer and Corporate Secretary, as interim Principal Financial Officer, effective September 8, 2025. Wilson joined Rocket in November 2021 and became Chief Corporate Officer in March 2024, bringing nearly 20 years of legal, compliance and executive experience in the life sciences industry, including senior roles at Ichnos Sciences and Teligent. The company states there are no family relationships or related-party transactions with Wilson beyond his existing compensation.
John Militello, Vice President of Finance, Treasurer and Principal Accounting Officer at Rocket Pharmaceuticals, Inc. (RCKT), reported two sales of common stock tied to RSU vesting. On 08/18/2025 he sold 699 shares at $3.065, leaving 56,285 shares beneficially owned. On 08/19/2025 he sold 361 shares at $2.996, leaving 55,924 shares owned. The filing states these shares were sold to pay tax withholding obligations related to Restricted Stock Units that convert one-for-one to common stock. The Form 4 was signed by an attorney-in-fact on 08/20/2025.
Jonathan David Schwartz, Chief Medical & Gene Therapy Officer at Rocket Pharmaceuticals (RCKT), reported two open-market transactions tied to vested restricted stock units. On 08/18/2025 he sold 1,680 shares at $3.065 per share and on 08/19/2025 he sold 805 shares at $2.996 per share; the filings state these sales were made to satisfy tax withholding obligations related to RSU vesting.
His beneficial ownership after the 08/18 transaction was reported as 222,414 shares and after the 08/19 transaction as 221,609 shares. The Form 4 was signed by an attorney-in-fact on 08/20/2025 and notes that his holdings include RSUs that convert one-for-one to common stock.
Martin L. Wilson, General Counsel and officer of Rocket Pharmaceuticals, reported sales of common stock tied to vested restricted stock units. On 08/18/2025 he sold 1,004 shares at $3.065 and on 08/19/2025 he sold 588 shares at $2.996 to satisfy tax withholding for RSU vesting. After these transactions he beneficially owned 135,462 shares. The filing notes RSUs convert one-for-one into common stock and that the sales were made specifically to cover tax obligations related to vesting.
Gaurav Shah, who is identified as both CEO and a Director of Rocket Pharmaceuticals, Inc. (RCKT), reported a transaction on 08/18/2025 on SEC Form 4. The filing shows 2,234 shares of common stock were disposed of at a price of $3.05 per share. The explanation states the shares were withheld by the company to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs) that convert one-for-one into common stock. After the withholding, Mr. Shah is reported to beneficially own 784,572 shares directly and holds additional indirect interests of 207,897 shares via spouse and 198,341 shares via the Gaurav D. Shah Irrevocable Trust. The form is signed on behalf of Mr. Shah by an attorney-in-fact on 08/20/2025.
Rocket Pharmaceuticals filed a current report stating that the U.S. Food and Drug Administration has lifted the clinical hold on its pivotal Phase 2 trial of RP‑A501, a gene therapy candidate for the treatment of Danon disease. This means the planned pivotal study can now proceed under FDA oversight. The company also issued a press release about this development, which is attached as an exhibit to the report.
Form 144 notice for Rocket Pharmaceuticals, Inc. (RCKT) shows a proposed sale of 588 common shares via Fidelity Brokerage Services with an aggregate market value of $1,761.77. The shares represent part of restricted stock that vested and were acquired on 08/15/2025 and were paid as compensation. The approximate sale date is 08/19/2025 on NASDAQ. The filing also discloses three recent sales by Martin Wilson during the past three months: 587 shares on 05/20/2025 (gross proceeds $3,783.80), 12,109 shares on 08/14/2025 ($36,553.44), and 1,004 shares on 08/18/2025 ($3,077.46). The filer certifies no undisclosed material adverse information.
Rocket Pharmaceuticals (RCKT) Form 144 notice shows an insider plans to sell 805 shares of common stock through Fidelity on 08/19/2025. The shares were acquired on 08/15/2025 by restricted stock vesting and paid as compensation. The filing discloses prior sales by Jonathan Schwartz: 801 shares on 05/20/2025 for $5,163.25, 11,161 shares on 08/14/2025 for $33,691.71, and 1,680 shares on 08/18/2025 for $5,149.54. The notice includes the required representation that the signer is unaware of undisclosed material adverse information.
Rocket Pharmaceuticals, Inc. (RCKT) notice reports proposed and recent insider transactions under Rule 144. An individual will offer 361 common shares held from a restricted stock vesting on 08/15/2025; the aggregate market value of the proposed sale is $1,081.63 and the shares are expected to be sold on 08/19/2025 on NASDAQ. The filing also discloses three prior sales by the same person during the past three months totaling 8,099 common shares for combined gross proceeds of $25,704.49. The filer attests they are unaware of any undisclosed material adverse information about the issuer.
Jonathan David Schwartz, Chief Medical & Gene Therapy Officer of Rocket Pharmaceuticals, Inc. (RCKT), reported a sale of 11,161 shares of common stock on 08/14/2025 at a reported price of $3.019 per share. The Form 4 shows Schwartz held 224,094 shares following the transaction. The filing states the sold shares were disposed to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units that convert one-for-one into common stock. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 08/18/2025.